EDIT vs VRTX
EDIT and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | EDITEDITAS MEDICINE, INC. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $397.77M | $135.35B |
| P/E (TTM) | — | 31.1 |
| P/B | — | 6.68 |
| P/S | 9.9x | 11.3x |
| Revenue | — | $12.59B(TTM) |
| Revenue growth (YoY) | 25.4% | 8.9% |
| Net income | — | $4.41B(TTM) |
| Earnings growth (YoY) | 32.5% | 838.1% |
| EPS, diluted | — | $17.17(TTM) |
| EBIT margin | -394.9% | 34.8% |
| ROE | -152.0% | 19.5% |
| ROIC | — | 25.0% |
| 1y total return | -14.7% | +25.5% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: EDIT vs VRTX
| 지표 | EDIT | VRTX |
|---|---|---|
| 최종 가치 | $1.0K | $60.8K |
| 총수익률 | -89.8% | +508.4% |
| CAGR | -19.8% | +19.1% |
| 변동성 | 83.6% | 32.6% |
| 샤프 | 0.09 | 0.57 |
| 소르티노 | 0.13 | 0.84 |
| 최대 낙폭 | -98.9% | -41.6% |
공통 거래일 2600일 기준, 2016-07-01 → 2026-11-03 · 무위험수익률 4.21% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)